Pain · 2008 · 174 citations · 47 references
MedicinePharmacologyPharmacotherapyPain ManagementPain MedicinePain ScienceAnalgesiaBotulinum Toxin TherapyBotulinum Toxin TreatmentInflammatory PainPain PhysiologyTrigeminal NeuralgiaHeat Pain ThresholdIntradermal AdministrationPain Pressure ThresholdPerceived PainSubcutaneous Drug AdministrationSubcutaneous Medication AdministrationTrigeminal Nerve PainVasomotor Symptoms
The present human study aimed at investigating the effect of subcutaneous administration of Botulinum toxin type A (BoNT/A) on capsaicin-induced trigeminal pain, neurogenic inflammation and experimentally induced cutaneous pain modalities. Fourteen healthy males (26.3+/-2.6 years) were included in this double-blind and placebo-controlled trial. The subjects received subcutaneous BoNT/A (22.5U) and isotonic saline in the mirror sides of their forehead. Pain and neurogenic inflammation was induced by four intradermal injections of capsaicin (100mug/muL) (before, and days 1, 3 and 7 after treatments). The capsaicin-induced pain intensity, pain area, the area of secondary hyperalgesia, the area of visible flare and vasomotor reactions were recorded together with cutaneous heat, electrical and pressure pain thresholds. BoNT/A reduced the capsaicin-induced trigeminal pain intensity compared to saline (F=37.9, P<0.001). The perceived pain area was smaller for the BoNT/A-treated side compared to saline (F=7.8, P<0.05). BoNT/A reduced the capsaicin-induced secondary hyperalgesia (F=5.3, P<0.05) and flare area (F=10.3, P<0.01) compared to saline. BoNT/A reduced blood flow (F(1,26)=109.5, P<0.001) and skin temperature (F(1,26)=63.1, P<0.001) at the capsaicin injection sites compared to saline and its suppressive effect was maximal at days 3 and 7 (P<0.05, post hoc test). BoNT/A elevated cutaneous heat pain thresholds (F=17.1, P<0.001) compared to saline; however, no alteration was recorded for electrical or pressure pain thresholds (P>0.05). Findings from the present study suggest that BoNT/A appears to preferentially target Cfibers and probably TRPV1-receptors, block neurotransmitter release and subsequently reduce pain, neurogenic inflammation and cutaneous heat pain threshold.
47
Impaired Nociception and Pain Sensation in Mice Lacking the Capsaicin Receptor
Michael J. Caterina, Andreas Leffler, Annika B. Malmberg et al. · Science · 2000 · 3.5K citations
Bartlett Ms · PubMed · 1947 · 1.1K citations
Neurogenic hyperalgesia: psychophysical studies of underlying mechanisms
Robert H. LaMotte, C. N. Shain, Donald A. Simone et al. · Journal of Neurophysiology · 1991 · 942 citations
M. S. Bartlett · Biometrics · 1947 · 928 citations
DOUBLE-BLIND STUDY OF BOTULINUM TOXIN IN SPASMODIC TORTICOLLIS
JosephK.C Tsui, A. Jon Stoessl, Andrew Eisen et al. · The Lancet · 1986 · 810 citations